MedDataX Logo

Hypertension and Cardiovascular Risk Factors

NCT ID: NCT00171782

Last Updated: 2023-10-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-02-29

Study Completion Date

2004-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

NCT00277472

Hypertension
COMPLETED PHASE4

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

NCT00698646

Hypertension
COMPLETED PHASE4

Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

NCT00171535

Hypertension
COMPLETED PHASE3

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

NCT00280540

Hypertension
COMPLETED PHASE4

A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension

NCT00241007

Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HYPERTENSION

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VALSARTAN+HYDROCHLOROTHIAZIDE

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Patients who give consent
* Men and women 18 to 80 years of age
* Patients with hypertension (systolic \>159 mm, diastolic \>100 mm)
* Patients meeting laboratory criteria

Exclusion Criteria

* \- Pregnant women
* Women not using approved contraception methods
* Secondary hypertension
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CVAH631BCO02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
NCT00170989 COMPLETED PHASE3
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension
NCT00273299 COMPLETED PHASE3
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
NCT00439738 COMPLETED PHASE4
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
NCT00171054 COMPLETED PHASE4
Comparison of Two Treatment Strategies in Hypertensive Patients
NCT00171444 COMPLETED PHASE4
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
NCT00170924 COMPLETED PHASE4
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
NCT00171353 COMPLETED PHASE4
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
NCT00241098 COMPLETED PHASE4
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
NCT00360178 COMPLETED PHASE3
Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
NCT00171561 COMPLETED PHASE4
Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
NCT00426478 COMPLETED PHASE4
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
NCT00902304 COMPLETED PHASE4
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
NCT00425997 COMPLETED PHASE4
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
NCT00350168 COMPLETED PHASE3
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
NCT00353912 COMPLETED PHASE3
A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
NCT00241137 COMPLETED PHASE3
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
NCT00351130 COMPLETED PHASE4
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
NCT00171015 COMPLETED PHASE3
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
NCT00338936 COMPLETED PHASE3
A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
NCT00171041 COMPLETED PHASE3
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
NCT00385931 COMPLETED PHASE3
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
NCT00171028 COMPLETED PHASE3
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
NCT00171093 COMPLETED PHASE3
Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
NCT00304226 COMPLETED PHASE4
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
NCT03180593 COMPLETED PHASE4